Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.77 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.58 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959389 | 0.88 | FFAR1 (0.68) | FFAR1FFAR4MAOBALOX5PTGS1 | |
| SCHEMBL1744939 | 0.87 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1 | |
| Benzyloxyphenylpropanoic Acid SCHEMBL1134648 | 0.87 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL9627289 | 0.86 | MAOB (0.68) | FFAR1FFAR4MAOBNR4A2 | |
| SCHEMBL9627732 | 0.86 | MAOB (0.68) | FFAR1FFAR4MAOBEPHX2NR4A2 | |
| Benzyloxyphenylpropanoic Acid SCHEMBL30117578 | 0.85 | FFAR1 (0.97) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL1747136 | 0.84 | FFAR1 (0.72) | FFAR1FFAR4MAOBAKR1B1LTA4H | |
| SCHEMBL1745247 | 0.84 | FFAR1 (0.72) | FFAR1FFAR4MAOBAKR1B1LTA4H | |
| SCHEMBL7951749 | 0.84 | FFAR1 (0.56) | FFAR1FFAR4ALDH1A1MAOBAKR1B1 | |
| SCHEMBL8010686 | 0.84 | FFAR1 (0.72) | FFAR1FFAR4ALDH1A1MAOBAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4460492-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | (INSERM) Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-13 | — | — | EP | disclosed |
| CN-118221532-A | Synthesis method of dobutamine hydrochloride | 上海现代哈森（商丘）药业有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131677-A1 | COMPOUNDS CONTAINING A HYDROXYPHENYL MOIETY AND THEIR USE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-9469665-B2 | Compound having lysophosphatidylserine receptor function modulation activity | THE UNIVERSITY OF TOKYO (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | TOHOKU UNIVERSITY (JP) | 2015-12-17 | — | — | US | disclosed |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2008047382-A2 | A PROCESS FOR THE PREPARATION OF 4-[2-[[3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]AMINO]ETHYL]-1,2-BENZENEDIOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047382-A2 | A PROCESS FOR THE PREPARATION OF 4-[2-[[3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]AMINO]ETHYL]-1,2-BENZENEDIOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-04-24 | — | — | WO | disclosed |
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | disclosed |
| US-4849453-A | ANIMAL GROWTH REGULATORS | ELI LILLY AND COMPANY (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0117647-B1 | IMPROVEMENTS IN OR RELATING TO PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1988-08-17 | — | — | EP | disclosed |
| US-4734437-A | PHENETHANOLAMINES | ELI LILLY AND COMPANY (US) | 1988-03-29 | — | — | US | disclosed |
| US-4690951-A | B-PHENETHANGLAMINES; FEED EFFICIENCY AND LEANESS | ELI LILLY AND COMPANY (US) | 1987-09-01 | — | — | US | disclosed |
| US-4673671-A | CONVERSION TO MONO O-PHOSPHATE ESTER | SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) | 1987-06-16 | — | — | US | disclosed |
| EP-0204948-A1 | Growth promotion of animals with phenethanol amines | ELI LILLY AND COMPANY (US) | 1986-12-17 | — | — | EP | disclosed |
| EP-0167204-A1 | Method for improving the absorption and effectiveness of a catecholamine compound | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1986-01-08 | — | — | EP | disclosed |
| EP-0117647-A1 | Improvements in or relating to phenethanolamines | ELI LILLY AND COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361119-A1 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY | LPAR1, LPAR3, LPAR2 | FFAR1 57/4885FFAR4 75/4885ALDH1A1 4724/4885 |
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | FFAR1 1990/4885FFAR4 681/4885ALDH1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.